ORIGINAL RESEARCH
Accepted on 25 Sep 2025
Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: Analysis of the FAERS database and disease-gene interaction network
doi 10.3389/fimmu.2025.1667249
- 246 views